How APAC Should Deploy AI to Find Hidden Lung Cancers

Why It Matters

Embedding AI into everyday imaging can close the detection gap for never‑smokers and relieve overstretched radiology services, accelerating early‑stage lung‑cancer treatment across the region.

Key Takeaways

• AI now routine in Malaysia, Indonesia, Vietnam, Philippines
• Never‑smoker lung cancers comprise about one‑third of East Asia cases
• CREATE study flagged 96% of biopsy‑confirmed cancers on chest X‑rays
• Key barriers: workflow integration, downstream capacity, and reimbursement
• Multi‑stakeholder deals like AstraZeneca‑Qure.ai accelerate national AI rollout

Pulse Analysis

The Asia‑Pacific region faces a rising lung‑cancer burden, amplified by a sizable cohort of never‑smokers who fall outside traditional low‑dose CT screening criteria. Health systems are strained by limited CT scanners, radiology workforce shortages, and fragmented digital infrastructure. In this context, artificial‑intelligence platforms that analyze chest X‑rays offer a pragmatic solution, turning every routine imaging encounter into a potential early‑detection opportunity without requiring new hardware investments.

AI‑enabled triage is especially valuable for the one‑third of East Asian lung‑cancer patients who have never smoked. By detecting subtle nodular patterns on standard chest X‑rays, algorithms can flag high‑risk cases that would otherwise be overlooked. The CREATE study, spanning 23 centres and screening over 185,000 individuals, demonstrated that 96% of biopsy‑confirmed cancers were correctly identified by AI, even when patients presented without respiratory symptoms. This real‑world evidence underscores AI’s role as a safety net, shifting diagnoses toward earlier, more treatable stages and reducing reliance on costly CT scans.

Scaling AI across APAC, however, confronts three persistent hurdles: seamless integration into existing PACS workflows, ensuring downstream capacity for confirmatory CT and specialist referral, and establishing clear reimbursement pathways. Multi‑stakeholder collaborations—exemplified by the AstraZeneca‑Qure.ai partnership—are emerging as the most effective model, aligning government health agendas, pharma’s trial infrastructure, and technology providers’ deployment expertise. As these alliances generate robust outcome data and demonstrate cost‑effectiveness, they pave the way for national AI‑driven lung‑cancer programs that can systematically lower missed‑cancer rates across diverse health economies.